Midostaurin plus chemotherapy showed to be efficacious in patients with newly diagnosed FLT3 mutated AML [11]; however, midostaurin has negligible activity in patients with relapsed or refractory AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.